Two Or More Barbituric Acid Compounds Or With An Additional Active Ingredient Or Stabilizer Patents (Class 514/271)
-
Patent number: 11058705Abstract: The invention provides derivatives of decitabine with superior chemical stability and shelf life, with similar physiological activity. The derivatives are provided in a non-aqueous formulation, which further stabilizes the derivatives. Methods of treating one or more myelodysplastic syndromes, leukemia, or solid tumours using the formulations are described.Type: GrantFiled: November 6, 2019Date of Patent: July 13, 2021Assignee: ASTEX PHARMACEUTICALS, INC.Inventors: Rajashree Joshi-Hangal, Chunlin Tang, Sanjeev Redkar, Harish Ravivarapu
-
Patent number: 11008293Abstract: The invention relates to a class of 5-carboxamide-2-thiobarbituric acid derivatives which inhibits human type II topoisomerase (topoII) enzyme and to use thereof as medicaments especially for blocking the proliferation of cancer cells and treating cancer. The invention also provides a method for the manufacture of the 5-carboxamide-2-thiobarbituric acid derivatives.Type: GrantFiled: March 15, 2018Date of Patent: May 18, 2021Assignees: UNIVERSITÀ DEGLI STUDI DI PADOVA, FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIAInventors: Marco De Vivo, Jose Antonio Ortego Martinez, Claudia Sissi, Jose Manuel Arencibia Jimenez
-
Patent number: 9211495Abstract: The degradation of an absorbent solution comprising organic compounds provided with an amine function in aqueous solution is reduced considerably in the presence of a small amount of degradation-inhibiting additives belonging to the class of derivatives of pyrimidine or of triazine, at least one substituent of which contains a sulfur atom. The absorbent solution is employed for deacidifying a gaseous effluent.Type: GrantFiled: November 19, 2010Date of Patent: December 15, 2015Assignee: IFP Energies nouvellesInventors: Bruno Delfort, P-Louis Carrette
-
Publication number: 20150141357Abstract: The present invention relates to methods of inhibiting shikimate pathway, comprising administering to a subject a pharmaceutically acceptable composition comprising a compound having a formula: or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: January 10, 2014Publication date: May 21, 2015Applicant: NATIONAL TSING HUA UNIVERSITYInventors: Wen-Ching Wang, Shih-Ching Chou, Ming-Hua Hsu
-
Publication number: 20150118295Abstract: Described are oral dosage forms that contain abuse-deterrent features and that contain core-shell polymers that include an active pharmaceutical ingredient, with particular examples including immediate release dosage forms that contain a drug that is commonly susceptible to abuse.Type: ApplicationFiled: September 12, 2014Publication date: April 30, 2015Inventors: Dinesh K. Haswani, Derek V. Moe, Victoria A. O'Neill, Manuel A. Vega Zepeda
-
Publication number: 20140323412Abstract: Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: October 26, 2012Publication date: October 30, 2014Inventors: Bronislava Gedulin, Michael Grey, Niall O'Donnell
-
Publication number: 20130108573Abstract: Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: October 26, 2012Publication date: May 2, 2013Applicant: Lumena Pharmaceuticals, Inc.Inventor: Lumena Pharmaceuticals, Inc.
-
Patent number: 8394808Abstract: The present invention relates to therapeutically active xanthine derivative compounds of Formula (I): corresponding processes for manufacture of said derivatives, pharmaceutical formulations containing and uses of such compounds in therapy, particularly in treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial.Type: GrantFiled: September 2, 2009Date of Patent: March 12, 2013Assignee: Glaxosmithkline LLCInventors: Ivan Leo Pinto, Shahzad Sharooq Rahman, Neville Hubert Nicholson
-
Publication number: 20120208773Abstract: The present invention provides for a pharmaceutical composition that includes tetrabenazine and a release-retarding agent; and a method of treating a hyperkinetic movement disorder (e.g., Huntington's disease, chorea associated with Huntington's disease, hemiballismus, senile chorea, tic disorders, tardive dyskinesia, myoclonus, dystonia and/or Tourette's syndrome). The method includes administering an effective amount of the pharmaceutical composition, for a period of time effective to treat the hyperkinetic movement disorder.Type: ApplicationFiled: August 12, 2010Publication date: August 16, 2012Applicant: Valeant International (Barbados) SRLInventors: Andrew John Duffield, Graham Jackson, Steven E. Frisbee, Okponanabofa Eradiri, John CK Lai
-
Publication number: 20120004251Abstract: This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is one of ethosuximide, valproate or phenobarbital.Type: ApplicationFiled: March 30, 2011Publication date: January 5, 2012Applicants: Otsuka Pharmaceutical Co., Limited, GW Pharma LimitedInventors: Ben Whalley, Claire Williams, Gary Stephens, Takashi Futamura
-
Publication number: 20110281811Abstract: The invention relates to the use of at least one leukotriene inhibitor for preparing a pharmaceutical composition for the prophylaxis and/or treatment of lung diseases, more particularly of bronchopulmonary dysplasia, in prematurely born infants. The invention further relates to a pharmaceutical composition for the prophylaxis and/or treatment of lung diseases, more particularly of bronchopulmonary dysplasia, in prematurely born infants, the pharmaceutical composition comprising at least one leukotriene inhibitor. The invention additionally relates to a method for the treatment and/or prophylaxis of a lung disease, more particularly of a bronchopulmonary dysplasia, in a prematurely born infant, where the prematurely born infant is administered a pharmacologically active amount of at least one leukotriene inhibitor.Type: ApplicationFiled: November 12, 2009Publication date: November 17, 2011Inventor: Sabine Rupprecht
-
Publication number: 20110263545Abstract: The present invention provides hepatoprotectant acetaminophen mutual prodrugs, which have an acetaminophen moiety covalently linked to a second moiety that may act as a hepatoprotectant against acetaminophen hepatotoxicity. Additionally, acetaminophen mutual prodrugs may have improved water solubility which may provide better suitability for parenteral and other dosage forms relative to administration of acetaminophen. Also provided are methods of treating a disease or condition that is responsive to acetaminophen (such as fever, pain and ischemic injury) using hepatoprotectant acetaminophen mutual prodrugs, as well as kits and unit dosages.Type: ApplicationFiled: May 20, 2009Publication date: October 27, 2011Inventors: Naweed Muhammad, Keith R. Bley, Jeffrey Tobias
-
Publication number: 20110172171Abstract: The present invention relates to taurine or taurine-like substances for the prevention of brain oedema, particularly brain intramyelinic oedema and more particularly brain intramyelinic oedema induced by an anti-convulsive drug such as vigabatrin. The invention relates to a substance selected from the group consisting of taurine, a taurine precursor, a taurine metabolite, a taurine derivative, a taurine analog and a substance required for the taurine biosynthesis for the prevention of brain oedema.Type: ApplicationFiled: September 4, 2009Publication date: July 14, 2011Inventors: Serge Picaud, José-Alain Sahel, Firas Jammoul
-
Publication number: 20110003835Abstract: This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors.Type: ApplicationFiled: September 3, 2010Publication date: January 6, 2011Applicant: CORTEX PHARMACEUTICALS, INC.Inventors: Rudolf Mueller, Leslie Street
-
Publication number: 20100190752Abstract: A composition of matter comprising in combination as component (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound, and as component (b) at least one antiepileptic, a pharmaceutical formulation and a dosage form comprising said composition of matter, and a method of treating pain, e.g. neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, whereby component (a) may be administered before or after component (b) and whereby components (a) or (b) are administered to the mammal either via the same or a different pathway of administration.Type: ApplicationFiled: January 26, 2010Publication date: July 29, 2010Applicant: Gruenenthal GmbHInventors: Klaus Schiene, Petra Bloms-Funke, Thomas Christoph
-
Patent number: 7696211Abstract: Methods and compositions for treating and preventing sepsis are provided. The methods of the invention comprise administering to a subject a therapeutically effective amount of an A1 adenosine receptor antagonist in combination with an antibiotic agent. The invention further encompasses pharmaceutical compositions comprising a combination of an A1 adenosine receptor antagonist and an antibiotic agent in a pharmaceutically acceptable carrier. The pharmaceutical compositions of the invention find use in methods for treating and preventing sepsis.Type: GrantFiled: April 27, 2006Date of Patent: April 13, 2010Inventor: Constance N. Wilson
-
Publication number: 20080268067Abstract: This invention relates to methods of inhibiting a Cav3 calcium channel in a cell using a C2-C10 alkyl alcohol, or mixtures thereof. This invention further relates to methods of treating a thalamocortical dysrhythmia disorder in a mammal and for treating a neurological disorder in a mammal associated with the thalamocortical dysrhythmia using a C2-C10 alkyl alcohol, a lipophilic molecule with a partition coefficient substantially similar to that of a C2-C10 alkyl alcohol, or mixtures thereof, or a pharmaceutical composition comprising the same.Type: ApplicationFiled: March 10, 2008Publication date: October 30, 2008Inventors: Rodolfo R. Llinas, Mutsuyuki Sugimori, Francisco Urbano
-
Patent number: 7276538Abstract: The use of the polyamine known as spermidine, i.e., N-(3-aminopropyl) tetraminethylenediamine, as an active principle in the preparation of a composition for pharmaceutical or dietetic use in man for combating hair loss is disclosed.Type: GrantFiled: January 17, 2003Date of Patent: October 2, 2007Assignee: Giuliani S.p.A.Inventors: Fabio Rinaldi, Elisabetta Sorbellini, Valter Gatti, Danila Ingrid Marchioretto
-
Patent number: 6974838Abstract: Methods of making and using racemic and optically pure metabolites of sibutramine, and pharmaceutically acceptable salts, solvates, and clathrates thereof, are disclosed. Pharmaceutical compositions and dosage forms are also disclosed which comprise a dopamine reuptake inhibitor, such as a racemic or optically pure sibutramine metabolite, and optionally an additional pharmacologically active compound.Type: GrantFiled: March 23, 2004Date of Patent: December 13, 2005Assignee: Sepracor Inc.Inventors: Chrisantha Hugh Senanayake, Qun Kevin Fang, Zhengxu Han, Dhileepkumar Krishnamurthy
-
Patent number: 6673925Abstract: Method of producing thiobarbituric acid derivatives of formula I wherein R1 is SH, S−M+ or CH3S—, and M+ is an alkali metal ion, by hydrogenolysis of a compound of formula II wherein R2 is chlorine or CH3O—, with a) a hydrogenolysis agent in the presence of an inert solvent and by a direct reaction of the hydrogenolysis product with an alkali metal methylate in methanol, or b) with a hydrogenolysis agent in the presence of an inert solvent and in the presence of a methylation reagent, and subsequently with an alkali metal methylate in methanol, as well as the use of these compound of formula I in the production of 7-[(4,6-dimethoxy-pyrimidin-2-yl)thio]-3-methylphthalide.Type: GrantFiled: August 20, 2001Date of Patent: January 6, 2004Assignee: Syngenta Crop Protection, Inc.Inventors: Bernhard Urwyler, Thomas Rapold, Marco Passafaro
-
Publication number: 20020156016Abstract: Gamma aminobutyric acid (GABA) is a potent inhibitory neurotransmitter that binds to hetero-oligomeric receptors in the mammalian brain. In a previous study, we documented specific GABA binding to isolated rat hepatocytes which resulted in inhibition of hepatocyte proliferation. The purpose of the present study was to define the nature of hepatic GABAA receptors and document their expression during rapid liver growth (post-partial hepatectomy). Polymerase chain reactions (PCR) with gene-specific primers derived from published sequences were performed with marathon-ready human and rat liver cDNA. Two GABAA receptor subunit types (&bgr;3 and &egr;) were expressed in the human liver and one (&bgr;3) in the rat liver. PCR amplification of the human GABAA receptor &bgr;3 subunit produced a single product (m.w. 53-59 kDa). In the case of the &egr; subunit, two PCR products were identified.Type: ApplicationFiled: March 28, 2002Publication date: October 24, 2002Inventor: Gerald Minuk
-
Patent number: 6469040Abstract: This invention relates to the use of cyclooxygenase-2 inhibitors or derivatives thereof in preventing and treating neoplasia. In particular, the invention describes the method of preventing and treating epithelial cell neoplasia in a subject, said method comprising treating the subject with a therapeutically-effective amount of a compound of Formula I. wherein A, R2 and R3 are as described in the specification.Type: GrantFiled: May 21, 2001Date of Patent: October 22, 2002Assignee: G.D. Searle & Co.Inventors: Karen Seibert, Jaime Masferrer, Gary B Gordon
-
Patent number: 6469017Abstract: A method for blocking IL-12 signaling by administration of the following compound: wherein, R1 is H, CH3, sulfate, phosphate, or salt thereof; R2 is alkyl (C1-12), alkoxyalkyl (C1-11), dialkoxyalkyl, CH2C6H5, —CH2-furan, biotin; and R3 is H, CH3 or CH2C6H5.Type: GrantFiled: January 16, 1998Date of Patent: October 22, 2002Assignee: Cell Therapeutics, Inc.Inventors: Stephen J. Klaus, J. Peter Klein, Anil M. Kumar
-
Patent number: 6358944Abstract: The present invention relates to methods and compositions comprising a very low dose of cyclobenzaprine or metabolite thereof for preventing and treating Generalized Anxiety Disorder. The present invention further relates to methods and compositions for treating and preventing symptoms associated with Generalized Anxiety Disorder using a very low dose of cyclobenzaprine.Type: GrantFiled: August 11, 2000Date of Patent: March 19, 2002Assignee: Vela Pharmaceuticals, Inc.Inventors: Seth Lederman, Iredell W. Iglehart, III
-
Patent number: 6169105Abstract: The power of citalopram, fluvoxamine and paroxetine to increase the availability of sarotonin, norepinephrine and dopamine, particularly serotonin, is augmented by administration in combination with a drug which is a serotonin 1A receptor antagonist.Type: GrantFiled: November 25, 1996Date of Patent: January 2, 2001Assignee: Eli Lilly and CompanyInventors: David Taiwai Wong, Juan Ignacio Oguiza
-
Patent number: 6028073Abstract: N-substitued 3-azabicyclo[3.2.0]heptane derivatives of formula (I) ##STR1## in which R.sup.1, R.sup.2, A, X, Y and Z have the meanings given in the description, their method of preparation and their use as pharmacological agents.Type: GrantFiled: September 18, 1998Date of Patent: February 22, 2000Assignee: BASF AktiengesellschaftInventors: Gerd Steiner, Rainer Munschauer, Thomas Hoger, Liliane Unger, Hans-Jurgen Teschendorf
-
Patent number: 6001842Abstract: Methods of preventing or treating ischemia-reperfusion injury in an organ by administration of a composition containing a selective A.sub.1 adenosine receptor antagonist and/or a P.sub.2X purinoceptor antagonist are provided. Methods of preventing or treating endotoxin-related tissue injury by administration of a composition containing a selective A.sub.1 adenosine receptor antagonist and/or a P.sub.2X purinoceptor antagonist are also provided.Type: GrantFiled: January 9, 1998Date of Patent: December 14, 1999Assignee: Trustees of the University of PennsylvaniaInventor: Constance F. Neely
-
Patent number: 5965564Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.Type: GrantFiled: March 20, 1998Date of Patent: October 12, 1999Assignee: Cell Therapeutics, Inc.Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
-
Patent number: 5880120Abstract: The present invention provides novel compounds such as certain aryloxy indanamines which are useful as anti-depressants and as inhibitors of synaptic norepinephrine and serotonin uptake. The present invention also provides an improvement in the treatment of depression which comprises inhibiting synaptic serotonin and epinepherine uptake.Type: GrantFiled: September 11, 1997Date of Patent: March 9, 1999Assignee: Merrell Pharmaceuticals, Inc.Inventor: Mark W. Dudley
-
Patent number: 5817666Abstract: A composition for the treatment of actinic keratoses includes 5-fluorouracil and an alpha hydroxy carboxylic acid. The composition may further include ancillary ingredients. A therapeutic method involving the composition and a kit for carrying out the treatment are also disclosed.Type: GrantFiled: February 13, 1997Date of Patent: October 6, 1998Inventor: Bruce E. Katz
-
Patent number: 5770607Abstract: This invention relates to an aqueous liquid composition for external use which contains a tricyclo compound of the chemical formula (I) presented here-under or a pharmaceutically acceptable salt thereof. More particularly, the invention relates to an aqueous liquid composition for external use characterized in that it contains said tricyclo compound and a water-soluble solubilizer. The composition of the invention is used in medical treatment.Type: GrantFiled: July 18, 1994Date of Patent: June 23, 1998Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Toshiyasu Honbo, Sachiyo Tanimoto, Hiromitsu Yoshida, Takehisa Hata, Sotoo Asakura, Yasuto Koyama, Youhei Kiyota
-
Patent number: 5668155Abstract: Disclosed are methods for improving various aberrant metabolic indices in mammals including humans by administration of muscarinic (particularly M1) receptor antagonists alone or in combination with prolactin inhibiting compounds. Preferably the administration takes place at a predetermined time (or, if a combination of muscarinic receptor antagonist and prolactin inhibitor is used, at different predetermined times) during a 24-hour period when the administration is effective (or its effect more pronounced). The invention has application in the treatment of lipid and glucose metabolism disorders.Type: GrantFiled: June 20, 1994Date of Patent: September 16, 1997Assignees: The General Hospital Corporation, The Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Anthony H. Cincotta, Albert H. Meier, John M. Wilson
-
Patent number: 5648357Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.Type: GrantFiled: September 16, 1994Date of Patent: July 15, 1997Assignee: Cell Therapeutics, Inc.Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
-
Patent number: 5635512Abstract: A process for the long term modification and regulation of linid and glucose metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia or hyperglycemia, or both (these being the hallmarks of noninsulin dependent, or Type II diabetes)--by administration to a vertebrate, animal or human, of a dopamine agonist and a prolactin stimulator. The dopamine agonist and prolactin stimulator are administered in daily dosages, respectively, at a time of day dependent on the normal circadian rhythm of fat and lean members of a similar species. Decreases in body fat deposits result by treatment of an obese species on a daily timed sequence based on circadian rhythms of the peak prolactin, or peak prolactin and peak glucocorticosteroid, blood level established for lean insulin sensitive members of a similar species.Type: GrantFiled: June 5, 1995Date of Patent: June 3, 1997Assignees: Ergo Science Incorporated, Board of Supervisors of Louisiana Business and Agricultural and Mechanical CollegeInventors: Anthony H. Cincotta, Albert H. Meier
-
Patent number: 5234929Abstract: A method of treating or preventing motion sickness is disclosed which comprises administering an anti-motion sickness effective amount of an anticonvulsant compound such as phenytoin, ethotoin, primidone, ethosuximide or carbamazepine, in combination with a potentiating amount of an antitussive or cough suppressant agent such as dextromethorphan, levopropoxyphene, muscaphene, pholocodeine, or carbetapentene. The antitussive compounds of the present invention act as potentiating agents so as to enable effective treatment or prevention of motion sickness using a reduced amount of the anticonvulsant compound normally used in such treatment. The method of the present invention reduces the potential for various side effects and thus provides a safer and more effective method of treatment for motion sickness than prior art methods.Type: GrantFiled: July 20, 1992Date of Patent: August 10, 1993Inventor: William Chelen
-
Patent number: 5141943Abstract: 5-benzyl barbiturate compounds for use as water-soluble uridine phosphorylase inhibitors are disclosed. These compounds are useful for reducing the toxicity and anemia induced by antiviral drugs such as AZT, as well as for potentiating anticancer drugs and combatting their host-toxicity.Type: GrantFiled: April 12, 1990Date of Patent: August 25, 1992Assignee: Brown University Research FoundationInventors: Fardos N. M. Naguib, Mahmoud H. el Kouni, Raymond Panzica, Sungman Cha
-
Patent number: 5130317Abstract: Pyrimidine-4,6-dicarboxylic acid diamides, processes for the use thereof, and pharmaceuticals based on these compoundsThe invention relates to pyrimidine-4,6-dicarboxylic acid diamides of the formula I ##STR1## in which R.sup.1 and R.sup.2 have the meanings given. The compounds according to the invention inhibit proline hydroxylase and lysine hydroxylase and can be employed as fibrosuppressants and immunosuppressants.Type: GrantFiled: September 19, 1990Date of Patent: July 14, 1992Assignee: Hoechst AktiengesellschaftInventors: Ekkehard Baader, Martin Bickel, Volkmar Gunzler-Pukall, Stephan Henke
-
Patent number: 4879274Abstract: Novel external medications comprise, as essential components, the following three components (A) to (C):(A) an .alpha.-monoglyceryl ether represented by the following formula (I): ##STR1## wherein R means an alkyl or alkenyl group having 10 - 24 carbon atoms; (B) a physiologically active material; and(C) an oily material.The external medications have extremely high skin occlusive properties and significantly-improved absorptivity of phosiologically active materials. Therefore, a smaller amount of the medications compared with the conventional ones can give sufficient pharmacological effects and thus side effects can be reduced. The external medications may contain physiologically active materials such as drugs, growth hormones and the like, which are expected to show pharmacological effects upon their percutaneous absorption.Type: GrantFiled: September 12, 1986Date of Patent: November 7, 1989Assignee: Kao CorporationInventors: Tetsuro Kamiya, Shuichi Tsuchiya, Kenji Hara
-
Patent number: 4602912Abstract: The invention relates to a composition for protecting keratinous material, in particular woollen textiles, from attack by pests that feed on keratin, in particular moth and beetle larvae, which composition contains, as active ingredient combination, a specifically substituted 5-(pyridyloxyphenylcarbamoyl)barbituric acid or a salt thereof and a synthetic pyrethroid, as well as to a process comprising the use of this active ingredient combination for providing said material with a protective finish against attack by pests that feed on keratin.Type: GrantFiled: June 24, 1985Date of Patent: July 29, 1986Assignee: Ciba-Geiby CorporationInventors: Bernardo de Sousa, Urs Burckhardt, Jean J. Gallay, Manfred Kuhne, Ernst Beriger, Dieter Reinehr
-
Patent number: 4503100Abstract: A composition for protecting keratin material, in particular woolen textiles, against attack by keratin pests, in particular moth and beetle larvae, which contains a specifically substituted 5-phenylcarbamoylbarbituric acid or a salt thereof and a synthetic pyrethroid as the active compound combination, is described, as well as a process, using the said active compound combination, for imparting a finish to the said material against attack by keratin pests.Type: GrantFiled: August 15, 1983Date of Patent: March 5, 1985Assignee: Ciba-Geigy CorporationInventors: Bernardo de Sousa, Werner Schmid, Klaus Artz